Our data suggest that simultaneously targeting the ECM stiffness-Hippo kinases-AMPK signaling and the low glucose-LKB1-AMPK signaling can be an effective therapeutic strategy against tumors with high stiffness, such as pancreatic ductal adenocarcinoma (PDAC). Here, PRKAA1 is linked to pancreatic ductal adenocarcinoma.